Biotech China 2014
The Chemotherapy Foundation Symposium XXVI OR Chemotherapy Foundation Symposium, Innovative Cancer Therapy for Tomorrow
The MARRIOTT MARQUIS
# 1535 Broadway
New York, New York
http://www.chemotherapyfoundationsymposium.org
The Chemotherapy Foundation Symposium XXVI
The Chemotherapy Foundation Symposium
The NEW YORK MARRIOTT MARQUIS  
#  1535 Broadway 
New York

Schedule of Presentations:

Tuesday, November 4, 2008
13:30:00 EASING OF SUFFERING IN CHILDREN WITH ADVANCED CANCER Joanne Wolfe
13:45:00 HEMATOPOIETIC CELL TRANSPLANTATION IN AML Elizabeth , Roman
14:00:00 UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION Vinod K. Prasad
14:15:00 JMML: DIAGNOSTIC AND TREATMENT CONSIDERATIONS Todd Cooper
14:30:00 NEW TRENDS IN PEDIATRIC HODGKIN'S LYMPHOMA Richard A. Drachtman
14:45:00 PEDIATRIC NON-HODGKIN'S LYMPHOMA Stan C. Goldman
15:00:00 Coffee Time
15:15:00 CURRENT CLINICAL TRIAL FOR RHABDOMYOSARCOMA Douglas Hawkins
15:30:00 LIMB-SPARING SURGERY FOR BONE SARCOMAS James C. Wittig
15:45:00 CHEMOTHERAPY FOR CHILDHOOD MALIGNANT BRAIN TUMORS James H. Garvin
16:00:00 SIMULTANEOUS INTERRUPTION OF METABOLIC PATHWAYS IN CHILDHOOD ALL Julio C. Barredo
16:15:00 ADVANCES IN TREATMENT STRATEGIES IN PEDIATRIC ALL Stephen E. , Sallan
16:30:00 Discussion
19:00:00 PROGRESS IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA Paul S. Gaynon
19:00:00 MEETING THE CLINICAL TRIAL CHALLENGES EMERGING FROM NOVEL BIOLOGICAL PLATFORMS Robert J Arceci
19:00:00 DINNER AND SPECIAL PRESENTATION
Wednesday, November 5, 2008
07:00:00 CHEMOTHERAPY INDUCED THROMBOCYTOPENIA: NEW DEVELOPMENTS IN PATHOPHYSIOLOGY AND TREATMENT James B. Bussel
07:00:00 BREAKFAST WITH THE PROFESSORS
07:00:00 DINNER AND PRESENTATIONS
07:00:00 AN UPDATE OF ESAs IN ONCOLOGY Jeffrey Crawford
08:00:00 MYELOPROLIFERATIVE/MYELODYSPLASTIC DISORDERS New Approaches and New Agents
08:00:00 MORNING SESSION
08:00:00 HEMATOLOGIC MALIGNANCIES George F. Atweh, Janice L. , Gabrilove, Janet Cuttner
08:00:00 WELCOME Steven J. Burakoff, Janice L. , Gabrilove, Edward P. Ambinder
08:10:00 MOLECULAR CHARACTERIZATION AND THERAPEUTIC TARGETS IN MPD Ronald Hoffman
08:25:00 JAK2 and MPL MUTATIONS Richard T. Silver
08:40:00 EPIGENETIC THERAPY IN MDS Hagop M. Kantarjian
08:55:00 VORELOXIN (SNS-595): AN ACTIVE AGENT IN AML Gail J Roboz
09:10:00 THERAPY FOR POST-IMATINIB FAILURES Jorges Cortes
09:25:00 APPROACH TO FRONT-LINE THERAPY IN CLL
09:40:00 LENALIDOMIDE AND RITUXIMAB IN CLL
09:55:00 FLAVOPIRODOL IN CLL Janice L. , Gabrilove
10:10:00 Coffee Time
10:40:00 LUMILIXIMAB STUDIES IN CLL Susan O’Brien
10:50:00 UPDATE on IMIDS in NHL Myron S. Czuczman
11:00:00 TARGETED THERAPY FOR DIFFUSE LARGE B-CELL LYMPHOMAS Ari M. Melnick
11:15:00 BORTEZOMIB AND LENALIDOMIDE-BASED TRIALS Sundar Jagannath
11:30:00 CARFILZOMIB: A NOVEL PROTEASOME INHIBITOR IN MYELOMA AND OTHER MALIGNANCIES Howard A. Burris
11:45:00 Discussion
12:00:00 AFTERNOON SESSION
12:00:00 Role of Transplantation William Bensinger
12:00:00 NEW DEVELOPMENTS IN MULTIPLE MYELOMA
12:00:00 Practical Applications of Clinical Trial Data Rav , Vij
12:00:00 LUNCH AND PRESENTATIONS
13:15:00 GI CANCERS Jordan Berlin
13:15:00 KEYNOTE ADDRESS
13:15:00 DILEMMAS IN ADJUVANT THERAPY FOR EARLY BREAST CANCER: THE NSABP EXPERIENCE Norman Wolmark
13:35:00 MODIFIED DOCETAXEL-BASED REGIMENS FOR ADVANCED GASTROESOPHAGEAL CANCERS Jaffer , Ajani
13:50:00 BIOMARKERS IN DECISION MAKING STAGE II COLON CANCER Anthony B. El-Khoueiry
14:00:00 NEW TYROSINE KINASE INHIBITORS FOR METASTATIC COLORECTAL CANCER Paulo M. Hoff
14:15:00 CAN CIRCULATING TUMOR CELLS BE A PREDICTIVE MARKER FOR TREATMENT OF COLON CANCER? Neal J. Meropol
14:25:00 SONIC HEDGEHOG: A NEW TARGET IN COLORECTAL CANCER?
14:40:00 NEW PARADIGMS IN TREATMENT OF OXALIPLATIN NEUROTOXICITY Howard S. Hochster
14:50:00 REDUCING RISK OF RECURRENT COLON POLYPS Eugene W. Gerner
15:00:00 Coffee Time
15:30:00 MELPHALAN IN NON-COLORECTAL METASTASES TO THE LIVER James , Pingpank
15:40:00 HEATED INTRAPERITONEAL CHEMOTHERAPY (HIPEC) IN METASTATIC GI MALIGNANCY Daniel M. Labow
15:50:00 PERSPECTIVES ON HIPEC THERAPY Elliot Newman
16:00:00 PANCREATIC CANCER: WHERE ARE WE GOING? Jordan Berlin
16:15:00 PHARMACOGENOMICS IN CANCER CLINICAL TRIALS Craig C. , Lockhart
16:30:00 SMALL CELL CARCINOMA OF THE GI TRACT Heine Hansen
16:45:00 Discussion
19:00:00 BENDAMUSTINE AND OTHER TARGETED AGENTS IN NHL Ann S. LaCasce
19:00:00 THERAPY OPTIONS FOR RITUXIMAB-REFRACTORY INDOLENT NHL John P. Leonard
21:00:00 End of the day
Thursday, November 6, 2008
07:00:00 GYNECOLOGICAL CANCERS
07:00:00 BREAKFAST WITH THE PROFESSORS
07:00:00 TARGETING VEGF RECEPTORS WITH PAZOPANIB: BIOLOGIC RATIONALE AND EMERGING CLINICAL DATA
07:00:00 LAPATINIB: PREVENTING METASTATIC COLONIZATION OF BC CELLS IN THE BRAIN Diane Palmieri
07:00:00 MORNING SESSION Carmel Cohen, Franco M. Muggia
08:00:00 INTRAPERITONEAL THERAPY FOR OVARIAN CANCER: MISSION ACCOMPLISHED? Franco M. Muggia
08:15:00 CISPLATIN RESISTANT OVARIAN CANCER: OXALIPLATIN OR PACLITAXEL? Britta Stordal
08:30:00 VORELOXIN (SNS-595) IN PLATINUM-RESISTANT OVARIAN CANCER William P. McGuire
08:45:00 NOVEL INTRAPERITONEAL STRATEGIES FOR MANAGING PLATINUM RESISTANCE Stephen B. Howell
09:00:00 TRABECTEDIN IN RECURRENT OVARIAN CANCER Bradley J Monk
09:15:00 NATIONAL AND INTERNATIONAL TRIALS IN OVARIAN CANCER William P. McGuire
09:30:00 HARNESSING THE IMMUNE SYSTEM FOR OVARIAN CANCER THERAPY Kunle Odunsi
09:45:00 EXPLOITING GENETIC DEFECTS WITH POLYMERASE INHIBITORS Hilary Calvert
10:00:00 Discussion
10:15:00 BRAIN
10:15:00 Coffee Time
10:45:00 UPDATE: PHASE II TRIAL OF CEDIRANIB IN RECURRENT GLIOBLASTOMA Elizabeth R. Gerstner
11:00:00 ATIPRIMOD PHASE II TRIAL FOR NEUROENDOCRINE CANCER Max W. , Sung
11:00:00 NEUROENDOCRINE
11:15:00 SARCOMA
11:15:00 ORAL DEFOROLIMUS IN METASTATIC SOFT-TISSUE AND BONE SARCOMAS
11:30:00 INTRAVENOUS REOLYSIN IN BONE OR SOFT TISSUE SARCOMA METASTIC TO LUNG Monica M. Mita
11:45:00 Discussion
12:00:00 AFTERNOON SESSION
12:00:00 LUNCH AND PRESENTATIONS
12:00:00 ADVANCES IN HCC THERAPY Josep M. Llovet
12:00:00 OVERVIEW OF ASIAN DATA ON HCC Bert H. O'Neil
12:00:00 BREAST CANCER
13:30:00 INNOVATIVE STRATEGIES FOR DRUG DEVELOPMENT Howard A. Burris
13:30:00 EZRA M. GREENSPAN MEMORIAL LECTURE
13:50:00 THE SELF-SEEDING MODEL OF CANCER: CLINICAL IMPLICATIONS Larry Norton
14:05:00 NEW ASSAYS TO DETERMINE HER2 STATUS Allan Lipton
14:20:00 FULVESTRANT: WHAT HAVE WE LEARNED FROM USING HIGHER DOSES? Irene Kuter
14:35:00 COMBINED ANTI-HER2 THERAPY: TRASTUZUMAB AND LAPATINIB Harold J. Burstein
14:50:00 TRASTUZUMAB-DM1, A NOVEL APPROACH TO THE TREATMENT OF HER2+ BREAST CANCER Ian E. Krop
15:05:00 Coffee Time
15:35:00 LAPULEUCEL-T IN IMMUNOTHERAPY OF BREAST CANCER: CLINICAL TRIAL DATA John Park
15:50:00 HER2 VACCINATION IN HIGH RISK BREAST CANCER George E. , Peoples
16:05:00 PROTEASOME INHIBITOR ENHANCES HORMONAL THERAPY IN BREAST CANCER Samuel Waxman
16:20:00 Discussion
16:20:00 THYROID
16:35:00 TREATMENT OF IODINE-RESISTANT ADVANCED THYROID CANCER Marcia S. Brose
16:45:00 HEAD AND NECK
16:45:00 OVERCOMING IMMUNOSUPPRESSION IN HEAD AND NECK CANCER WITH CITOPLURIKIN (IRX-2) Jeffrey S. Moyer
16:55:00 Discussion
19:00:00 PERSONALIZED MEDICINE: TREATMENT DECISION-MAKING Norman Wolmark
19:00:00 DINNER AND PRESENTATIONS
21:00:00 End of the day
Friday, November 7, 2008
07:00:00 BREAKFAST WITH THE PROFESSORS
07:00:00 URO-ONCOLOGY
07:00:00 THE CONTROVERSY: ARE ANTHRACYCLINES NECESSARY FOR EARLY BREAST CANCER? Stephen E. Jones
07:00:00 UPDATE ON CHEMOTHERAPY FOR ADVANCED BREAST CANCER Stephen Y. Chan
07:00:00 MORNING SESSION
08:00:00 PROSTATE
08:00:00 ENDOTHELIAL A: SURVIVAL AND BONE METASTASES IN HRPC Nancy A. Dawson
08:15:00 VACCINE APPROACHES IN EARLY STAGE PC Robert S. DiPaola
08:30:00 ABIRATERONE ACETATE: AN ANDROGEN WITHDRAWAL RESPONSIVE PHENOTYPE IN CRPC Eleni Efstathiou
08:45:00 DEVELOPING COMBINATION STRATEGIES WITH HISTONE DEACETYLASE INHIBITORS
08:45:00 DEVELOPING COMBINATION STRATEGIES WITH HISTONE DEACETYLASE INHIBITORS Roberto , Pili
08:45:00 RENAL
08:55:00 PHARMACODYNAMIC TRIAL OF FLT-PET/CT IMAGING IN SUNITINIB-TREATED RENAL CELL CARCINOMA Glenn Liu
09:10:00 Discussion
09:10:00 LUNG CANCER
09:10:00 Discussion
09:25:00 ROLE OF MAINTENANCE THERAPY IN ADVANCED NSCLC Chandra P. Belani
09:40:00 EGFR INHIBITORS IN NSCLC AND HOW TO SELECT PATIENTS Fred R. Hirsch
09:55:00 EVOLVING ROLE OF SUNITINIB IN NSCLC Mark A. Socinski
10:05:00 Coffee Time
10:20:00 TALACTOFERRIN IN REFRACTORY NSCLC Giuseppe Giaccone
10:30:00 PERSONALIZED THERAPY APPROACHES FOR ADVANCED NSCLC Roy S. Herbst
10:45:00 THIRD LINE THERAPY FOR NSCLC AND BEYOND Cory , Langer
11:00:00 PHASE II STUDY OF PICOPLATIN FOR 2ND LINE SCLC John R. , Eckhardt
11:10:00 UPDATE ON AMRUBICIN IN SCLC Robert M. Jotte
11:20:00 PHASE I/II STUDY OF DOCETAXEL PLUS OBATOCLAX (GX17-070) IN RELAPSED NSCLC Alberto A. Chiappori
11:30:00 MAG3 VACCINATION FOR LUNG CANCER Nasser Altorki
11:40:00 LUNG CANCER VACCINE L-BLP25 Nevin Murray
11:50:00 Discussion
12:00:00 ASA-404: A NOVEL VASCULAR DISRUPTING AGENT FOR LUNG CANCER THERAPY Primo Jr. N. Lara
12:00:00 LUNCH AND PRESENTATIONS
12:00:00 EVEROLIMUS FOR RENAL CELL CARCINOMA Robert J. Motzer
13:15:00 DIVERSE THERAPEUTICS
13:15:00 AFTERNOON SESSION
13:15:00 IMMUNE THERAPY FOR OVARIAN CANCER: ARE WE READY TO LAUNCH? George Coukos
13:15:00 JUDAH FOLKMAN MEMORIAL LECTURE
13:35:00 MELANOMA
13:35:00 STAGING AND PROGNOSTIC CRITERIA Charles M. Balch
13:50:00 SYSTEMIC ADH-1 AND MEPHALAN ILI IN ADVANCED EXTREMITY Douglas S. Tyler
14:05:00 THE EVOLUTION OF OBLIMERSEN Anna C Pavlick
14:15:00 IMMUNOTHERAPY
14:15:00 RADIOTHERAPY WITH IMMUNOTHERAPY Silvia C Formenti
14:25:00 SOLID TUMORS
14:25:00 NOVEL ANTICANCER AGENTS IN THE NCI CTEP CLINICAL DEVELOPMENT PROGRAM John J. Wright
14:40:00 AMG386: A FIRST-IN-CLASS ANGIOPOIETIN TARGETED THERAPY Alain C. Mita
14:50:00 TERAMEPROCOL INFUSION FOR REFRACTORY SOLID TUMORS Jeffrey Infante
15:00:00 Coffee Time
15:15:00 ENILURACIL: CLINICAL UPDATE ON NOVEL SCHEDULES WITH A DPD-INHIBITOR Howard A. Burris
15:25:00 OTHER CLINICAL OPTIONS
15:25:00 EVALUATION OF MLN 8237: A NOVEL AURORA A KINASE INHIBITOR E. Claire Dees
15:35:00 RECENT DATA FROM THE Z-FAST AND ZO-FAST TRIALS Allan Lipton
15:45:00 AERODIGESTIVE CANCER PREVENTION Alex A Adjei
16:00:00 GENERIC TREATMENT PLAN TEMPLATE Joseph Jacobson
16:15:00 LATE BREAKING DEVELOPMENTS
16:45:00 Discussion
19:00:00 CETUXIMAB IN NSCLC Thomas J. Lynch
19:00:00 DINNER AND PRESENTATIONS
19:00:00 CHANGING PARADIGMS IN THE THERAPEUTIC APPROACH TO ADVANCED NSCLC Mark A. Socinski
21:00:00 End of the day
Saturday, November 8, 2008
06:55:00 NEW PERSPECTIVES IN ONCOLOGY PRACTICE
07:00:00 Registration & Continental Breakfast
08:00:00 OPENING REMARKS Andrea Downey, Shannon B. , Holloway
08:10:00 NOVEL THERAPEUTICS FOR MELANOMA Anna C Pavlick
08:30:00 WHEN YOUR PATIENT DIES: PERSONAL GRIEF IN THE PROFESSIONAL SETTING Nora , Rightmer
08:50:00 MYELODYSPLATIC SYNDROME: SUPPORTIVE CARE TO ACTIVE TREATMENT Sandra L. Allen-Bard
09:10:00 MAKING THE LAW WORK FOR YOU AND YOUR PATIENT: DOCUMENTING & PRESCRIBING CONTROLLED SUBSTANCES Jennifer Bolen
09:35:00 NEW ADVANCES IN mTor THERAPY Andrea Rustine
09:55:00 CHEMOBRAIN & COGNITIVE FUNCTION Lynne I. Wagner
10:15:00 BREAK
10:35:00 DEALING WITH EMOTIONS, STRENGTHENING RELATIONSHIPS Robert A. , Buckman
10:35:00 KEYNOTE ADDRESS
11:05:00 THE CHANGING PRACTICE MANAGEMENT ENVIRONMENT Joseph S. Bailes
11:25:00 TRANSPLANT-RELATED INFECTIONS: THE CHALLENGE CONTINUES Angela Johns
11:45:00 USE OF METHADONE IN CANCER TREATMENT Nessa Coyle
12:05:00 LUNCH
13:15:00 VIDEO: CANCER THROUGH THE EYES OF THE PATIENT AND FAMILY Teresa Gilewski
13:40:00 PATIENT-CENTRIC QUALITY ONCOLOGY CARE Edward P. Ambinder
14:00:00 EMERGING TRENDS IN MULTIPLE MYELOMA TREATMENT Faiza Zafar
14:20:00 PALLIATIVE INTERVENTIONS IN THE ONCOLOGY WORLD Christopher , Comfort
14:40:00 ADHERENCE TO THERAPY: IT MAY BE A BIGGER ISSUE THAN YOU REALIZE Cathy Maxwell,
15:00:00 TRENDS IN THE MANAGEMENT OF COLORECTAL CANCER Shannon B. , Holloway
15:40:00 EMERGING TRENDS IN THE MANAGEMENT OF VTE IN CANCER PATIENTS EDITH A. NUTESCU
16:00:00 CLOSING REMARKS Andrea Downey, Shannon B. , Holloway
16:00:00 End of the day
4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.